Hoth Therapeutics, Inc. (HOTH): Price and Financial Metrics
GET POWR RATINGS... FREE!
HOTH Stock Price Chart Interactive Chart >
HOTH Price/Volume Stats
|Current price||$1.26||52-week high||$3.50|
|Prev. close||$1.25||52-week low||$1.14|
|Day high||$1.27||Avg. volume||2,321,501|
|50-day MA||$1.32||Dividend yield||N/A|
|200-day MA||$1.73||Market Cap||30.08M|
Hoth Therapeutics, Inc. (HOTH) Company Bio
Hoth Therapeutics, Inc. is a development stage biopharmaceutical company, which engages in the provision and development of therapeutic platform. The company focuses on the patients suffering from conditions such as atopic dermatitis, also known as eczema. It offers BioLexa Platform, a proprietary, patented, drug compound platform for the treatment of eczema. The company was founded by Robbie Knie, Matthew D. Eitner, and James Ahern in May 2017 and is headquartered in New York, NY.
Most Popular Stories View All
HOTH Latest News Stream
|Loading, please wait...|
HOTH Latest Social Stream
View Full HOTH Social Stream
Latest HOTH News From Around the Web
Below are the latest news stories about Hoth Therapeutics Inc that investors may wish to consider to help them evaluate HOTH as an investment opportunity.
Hoth Therapeutics Announces Positive Phase 1b Results for Completed First Cohort of Patient Trial of BioLexa
Today, Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient focused biopharmaceutical company, announced the completed safety results in Cohort 1 of its first in human clinical trial of the proprietary BioLexa platform to treat atopic dermatitis, also known as eczema.
Hoth Therapeutics, Inc. (NASDAQ: HOTH), a clinical-stage biopharma engaged in the development of therapies for unmet need, releases positive early-stage data for its BioLexa platform. What Happened: New York-based Hoth says data from the Cohort 1 of a two-part, Phase 1b study of BioLexa showed no serious adverse events and no drug-related treatment-emergent adverse events. BioLexa is Hoth's proprietary antimicrobial topical formulation being developed for the treatment of diseases mediated by St
Thinking about buying stock in CohBar, Mogo, BioCryst Pharmaceuticals, Hoth Therapeutics, or Maravai Lifesciences?
NEW YORK, Aug. 11, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for CWBR, MOGO, BCRX, HOTH, and MRVI. To see how InvestorsObserver''s proprietary scoring system rates these stocks, view the InvestorsObserver''s PriceWatch Alert by selecting the corresponding link.
Hoth Therapeutics'' mRNA ''Frameshifting'' Therapy HT-KIT for Mast Cell Cancers Reduces Size, Spread - Research Published in Molecular Therapy
NEW YORK, Aug. 11, 2021 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient-focused biopharmaceutical company, today highlights recent findings from North Carolina State University, that its new treatment for mast cell cancers, known as HT-KIT, reduces the number of mast
Hoth Therapeutics' mRNA 'Frameshifting' Therapy HT-KIT for Mast Cell Cancers Reduces Size, Spread - Research Published in Molecular Therapy
Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient-focused biopharmaceutical company, today highlights recent findings from North Carolina State University, that its new treatment for mast cell cancers, known as HT-KIT, reduces the number of mast cells by "mutating" the messenger RNA (mRNA) before it can deliver instructions for manufacturing the gene responsible for cell proliferation.
HOTH Price Returns